Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Classical hematology 4

Conditions

Carcinoma, Non-Small-Cell Lung 42Breast Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 23Neoplasms 22Multiple Myeloma 18Leukemia, Myeloid, Acute 14Neoplasm Metastasis 11Carcinoma, Renal Cell 10Leukemia 10Melanoma 10Ovarian Neoplasms 10Recurrence 10Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Adenocarcinoma 8Carcinoma, Hepatocellular 8Colorectal Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lung Neoplasms 8Myelodysplastic Syndromes 8Prostatic Neoplasms 8Stomach Neoplasms 8Lymphoma, Follicular 7Bronchiolitis Obliterans Syndrome 6Carcinoma 6Lymphoma 6Lymphoma, Non-Hodgkin 6Small Cell Lung Carcinoma 6Urinary Bladder Neoplasms 6Cholangiocarcinoma 5

Interventions

voxelotor 1maltodextrin 1Glutamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Has announcements × Anemia, Sickle Cell × Clear all
NCT03036813 2023-07-27

GBT_HOPE

Pfizer

Phase 3 Completed
449 enrolled 17 charts 1 FDA
Classical hematology

Anemia, Sickle Cell

NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Emmaus Medical, Inc.

Phase 3 Completed
230 enrolled 19 charts 1 FDA
Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

NCT02516579 2020-03-19

ESCORT-HU

Theravia

Completed
1,906 enrolled 9 charts 1 FDA
Classical hematology

Anemia, Sickle Cell

NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed
198 enrolled 18 charts 1 FDA
Classical hematology

Anemia, Sickle Cell, Priapism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡